Clinical Trial Search

Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale

Primary: Number of Subjects That Showed no Significant Irritation — 0 participants

Primary: Grading Scale for Visual Evaluation of Skin Condition — 0; 0; 0; 0 Scores Ranging (0-7)

Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score

Primary: Comparative Assessment of Facial Irritation and Cutaneous Effects. — 1.1; 2.7; 3.2; 6.2 Scores on a Scale

Primary: Skin Irritation Score — 0; 0; 339; 15 Normalized cumulative irritation score — p=<0.0001

Primary: Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin — 1.00; 2.46; 1.34; 0.58 units on a scale

Primary: Number of Subjects That Showed Erythema Based on 5 Point Scoring Scale — 0 Participants

Primary: Assessment of Facial Irritation and Cutaneous Effects — 4.8; 3.9; 8.8; 6.7 Ordinal data treated as interval

Primary: Facial Irritation and Cutaneous Effects — 1.5; 5.4; 3.1; 7.8 Scores on a Scale

Primary: Skin Sensitization Reaction Using Berger and Bowman Scale — 0; 0; 0; 0 score on a scale

Primary: Change in Total Symptom Score — -5; 2 score on a scale

Primary: Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 — 2; 1; 1; 0 Number of participants

Primary: Expert Grader Assessment - Erythema — 0.0; 0.0; 0.4; 2.0 Scores on a Scale

Primary: Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix — 53; 49; 0; 4 Participants

Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 3 — 0; 0 Score on scale

Primary: Proportion of Participants With Skin Irritation Scores at 24 Hours — 75.0; 91.7; 94.4; 94.4 Percentage of participants

Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants

Primary: Mean Change From Baseline in Daily rTNSS Over the Entire Treatment Period (28 Days) — -2.10; -2.17 points on a scale — p=0.845

Primary: Frequency of Dermal Response Score at 15-30 Minutes Post Patch Removal — 0; 0; 0; 0 Participants

Primary: Cumulative Irritation Total (CIT) Score — 0.0; 20.0; 0.0 Score on a scale

Primary: Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans. — 1.10; 0.70; 1.10; 49.15 score on a scale

Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change

Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants

Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale

Primary: Erythema Rating Scale — 0.6; 0.7 units on a scale

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0 participants

Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants

Primary: Number of Patients That Showed Sensitization Reaction to the Test Material at Challenge — 0 Participants

Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants